Tracking new treatments for rare nerve disease
NCT ID NCT06885957
Summary
This study is a registry that will track 200 adults in China who have a specific type of neuromyelitis optica spectrum disorder (NMOSD) and are already receiving a monoclonal antibody treatment. The goal is to see how well these treatments work and how safe they are in real-world, everyday medical practice. Researchers will also look at brain scans and blood tests to understand how the disease changes over time with treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMO SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.